Phospholipase D1 drives a positive feedback loop to reinforce the Wnt/β-catenin/TCF signaling axis

Cancer Research

Volumn 70, Issue 10, 2010, Pages 4233-4242

  Kang, Dong Woo ^a   Lee, Soung Hoon ^b   Yoon, Jeong Whan ^c   Park, Won Sang ^c   Choi, Kang Yell ^b   Min, Do Sik ^a  

^a Pusan National University   (South Korea)

^b Yonsei University   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3; PHOSPHATIDIC ACID; PHOSPHOLIPASE D1; T CELL FACTOR PROTEIN; WNT PROTEIN; WNT3A PROTEIN;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; GENE TARGETING; HUMAN; HUMAN CELL; POSITIVE FEEDBACK; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BETA CATENIN; BLOTTING, WESTERN; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; FEEDBACK, PHYSIOLOGICAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPRECIPITATION; NEOPLASMS; PHOSPHOLIPASE D; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; WNT PROTEINS;

EID: 77952853804     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3470     Document Type: Article

References (46)

1. Huang P, Frohman MA. The potential for phospholipase D as a new therapeutic target. Expert Opin Ther Targets 2007;11:707-716 (Pubitemid 46730084)
2. Exton JH. Phospholipase D-structure, regulation and function. Rev Physiol Biochem Pharmacol 2002;144:1-94.
3. Foster DA, Xu L. Phospholipase D in cell proliferation and cancer. Mol Cancer Res 2003;1:789-800.
4. Wymann MP, Schneiter R. Lipid signaling in disease. Nat Rev Mol Cell Biol 2008;9:162-176
5. Kang DW, Park MH, Lee YJ, et al. Phorbol ester up-regulates phospholipase D1 but not phospholipase D2 expression through a PKC/ras/ERK/NFκB- dependent pathway and enhances matrix metalloproteinase-9 secretion in colon cancer cells. J Biol Chem 2008; 283:4094-4104
6. Saito M, Iwadate M, Higashimoto M, Ono K, Takebayashi Y, Takenoshita S. Expression of phospholipase D2 in human colorectal carcinoma. Oncol Rep 2007;18:1329-1334
7. Noh DY, Ahn SJ, Lee RA, et al. Overexpression of phospholipase D in human breast cancer tissues. Cancer Lett 2000;161:207-214
8. Zhao Y, Ehara H, Akao Y, et al. Increased activity and intranuclear expression of phospholipase D2 in human renal cancer. Biochem Biophys Res Commun 2000;278:140-143
9. Uchida N, Okamura S, Kuwano H. Phospholipase D activity in human gastric carcinoma. Anti-Cancer Res 1999;19:671-675 (Pubitemid 29168314)
10. Kim YR, Byun HS, Won M, et al. Modulatory role of phospholipase D in the activation of signal transducer and activator of transcription (STAT)-3 by thyroid oncogenic kinase RET/PTC. BMC Cancer 2008;8:144-154
11. Min DS, Kwon TK, Park WS, et al. Neoplastic transformation and tumorigenesis associated with overexpression of phospholipase D isozymes in cultured murine fibroblasts. Carcinogenesis 2001;22: 1641-1647
12. Park MH, Ahn BH, Hong YK, Min DS. Overexpression of phospholipase D enhances matrix metalloproteinase-2 expression and glioma cell invasion via protein kinase C and protein kinase A/NF-κB/Sp1-mediated signaling pathways. Carcinogenesis 2009;30: 356-365
13. Buchanan FG, McReynolds M, Couvillon A, et al. Requirement of phospholipase D1 activity in H-RasV12-induced transformation. Proc Natl Acad Sci U S A 2005;102:1638-1642 (Pubitemid 40209220)
14. Morin PJ. β-Catenin signaling and cancer. Bioassays 1999;21: 1021-1030
15. Nusse R. Wnt signaling in disease and in development. Cell Res 2005;15:28-32.
16. Kikuchi A. Tumor formation by genetic mutations in the components of the Wnt signaling pathway. Cancer Sci 2003;94:225-229 (Pubitemid 36575886)
17. Behrens J. The role of the Wnt signalling pathway in colorectal tumorigenesis. Biochem Soc Trans 2005;33:672-675 (Pubitemid 41160836)
18. Hsu SC, Galceran J, Grosschedl R. Modulation of transcriptional regulation by LEF-1 in response to Wnt-1 signaling and association with β-catenin. Mol Cell Biol 1998;18:4807-4818 (Pubitemid 28343065)
19. van Es JH, Barker N, Clevers H. You Wnt some, you lose some: oncogenes in the Wnt signaling pathway. Curr Opin Genet Dev 2003; 13:28-33. (Pubitemid 36143924)
20. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998;281:1509-1512 (Pubitemid 28425575)
21. Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A 1999;96:5522-5527 (Pubitemid 29234650)
22. Crawford HC, Fingleton BM, Rudolph-Owen LA, et al. The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors. Oncogene 1999;18:2883-2891
23. Xu L, Corcoran RB, Welsh JW, Pennica D, Levine AJ. WISP-1 is a Wnt-1- and β-catenin-responsive oncogene. Genes Dev 2000;4: 585-595
24. Zhang T, Otevrel T, Gao ZQ, et al. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res 2001;61:8664-8667 (Pubitemid 34013874)
25. Araki Y, Okamura S, Hussain SP, et al. Regulation of cyclooxygenase-2 expression by the Wnt and Ras pathways. Cancer Res 2003;63:728-734 (Pubitemid 36158154)
26. Du Q, Park KS, Guo Z, et al. SP Regulation of human NOS2 expression by wnt/β-catenin signaling. Cancer Res 2006;66:7024-7031 (Pubitemid 44197678)
27. Ahn BH, Kim SY, Kim EH, et al. Transmodulation between PLD and c-Src enhances cell proliferation. Mol Cell Biol 2003;23: 3103-3115 (Pubitemid 36459225)
28. Caretti G, Salsi V, Vecchi C, Imbriano C, Mantovani R. Dynamic recruitment of NF-Y and hats on cell-cycle prometers. J Biol Chem 2003;278:30435-30440
29. Min DS, Ahn BH, Rhie DJ, et al. Expression and regulation of phospholipase D during neuronal differentiation of PC12 cells. Neuropharmacology 2001;41:384-391 (Pubitemid 32772933)
30. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 1996;6:1664-1668 (Pubitemid 27050234)
31. Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by pharmacological GSK-3β-specific inhibitor. Nat Med 2004;10:55-63. (Pubitemid 38524699)
32. Suzuki H, Toyota M, Carraway H, et al. Frequent epigenetic inactivation of Wnt antagonist genes in breast cancer. Br J Cancer 2008;98: 1147-1156 (Pubitemid 351399804)
33. Schlosshauer PW, Brown SA, Eisinger K, et al. APC truncation and increased β-catenin levels in a human breast cancer cell line. Carcinogenesis 2000;21:1453-1456 (Pubitemid 30456006)
34. van de Wetering M. The β-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 2002;111: 241-250
35. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 2003;1653:1-24. (Pubitemid 36627817)
36. Ilyas M, Tomlinson IP, Rowan A, Pignatelli M, Bodmer WF. β-Catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci U S A 1997;94:10330-10334 (Pubitemid 27407041)
37. Li J, Wang CY. TBL1Â-TBLR1 and β-catenin recruit each other to Wnt target-gene promoter for transcription activation and oncogenesis. Nat Cell Biol 2008;10:160-169 (Pubitemid 351194045)
38. Korinek V, Barker N, Morin P, et al. Constitutive transcriptional activation by a β-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997;275:1784-1787 (Pubitemid 27136714)
39. Smith KJ, Johnson KA, Bryan TM, et al. The APC gene product in normal and tumor cells. Proc Nati Acad Sci U S A 1993;90:2846-2850 (Pubitemid 23113514)
40. Scott SA, Selvy PE, Buck JR, et al. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol 2009;5:1008-1017
41. Su W, Yeku O, Olepu S, et al. 5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis. Mol Pharmacol 2009;75:437-446
42. Kikuchi R, Murakami M, Sobue S, et al. Ewing's sarcoma fusion protein, EWS/Fli-1 and Fli-1 protein induce PLD2 but not PLD1 gene expression by binding to an ETS domain of 5′ promoter. Oncogene 2007;26:1802-1810
43. Takemaru K, Yamaguchi S, Lee YS, et al. Chibby, a nuclear β-catenin-associated antagonist of the Wnt/Wingless pathway. Nature 2003; 422:905-909 (Pubitemid 36520044)
44. Daniels DL, Weis WI. β-Catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation. Nat Struct Mol Biol 2005;12:364-371
45. Tago K, Nakamura T, Nishita M, et al. Inhibition of Wnt signaling by ICAT, a novel β-catenin-interacting protein. Genes Dev 2000;14: 1741-1749 (Pubitemid 30602993)
46. Zoltewicz JS, Ashique AM, Choe Y, et al. Wnt signaling is regulated by endoplasmic reticulum retention. PLoS ONE 2009;4:e6191.